|
Search
Search through the thousands of lawsuits, complaints and recalls on our site.
|
FDA Class I Classification Given to Baxter's Sept. 2005 Urgent Product Recall for Meridian Hemodialysis InstrumentDate: 1/10/2006
Reason: There have been reports of hemolysis (broken blood cells) related to kinks in the blood tubing sets used with the Meridian.
Distribution: Nationwide.
The Food and Drug Administration (FDA) released the following information: Specifically, there have been reports of hemolysis (broken blood cells) related to kinks in the blood tubing sets used with the Meridian. To date, there have been reports of one death and at least one serious injury, associated with kinking of blood tubing sets routed through both channels of the clips mounted on the front of the Meridian. The clinical implication of returning hemolyzed blood to a patient can range from no adverse health consequences up to and including death. Class I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of the affected product may cause serious injury or death if the problem is not corrected. To help customers address this issue, Baxter provided labels with the September 28, 2005 customer letter, to be affixed to Meridian instruments. The labels clearly display the proper routing of the blood tubing sets. Further, Baxter asks that all care providers be trained and that they follow the proper set up and use only one of the two retainers in each of the double-tubing clips during treatment. Continuous verification through visual inspection of the tubing will reduce the chances of kinking. In addition, Baxter will be providing modified tubing clips to eliminate related safety issues as soon as possible. Baxter's letter to customers is available on its web site at www.baxter.com. The last Meridian was manufactured in 2002. Approximately 2,100 Meridian instruments are currently in use, including 1,700 in the United States. Baxter announced in July 2005 that it would no longer manufacture any hemodialysis instruments and the company has been working to transition customers to alternate hemodialysis instruments through a distribution arrangement with Gambro Renal Products. Specific to the Meridian, Baxter has already initiated a transition of Meridian instruments in the field to Gambro instruments. The costs associated with this transition plan have been included in a previously announced charge estimated to be approximately $50 million, which has been partially recorded in the third quarter of 2005 and the remaining charge will be recorded in subsequent quarters. Customers requesting copies or with questions regarding the September 28, 2005 letter, or the FDA's classification of this action, or who need technical assistance, may contact the company at 1-800-4BAXTER (1-800-422-9837). If you are a physician or a patient who has experienced a problem with the Meridian device, please send a report to FDA's MedWatch program. Information regarding FDA's MedWatch program is available at http://www.fda.gov/medwatch or call 1-800-332-1088. Type of Recall: Other Drugs / Medicines Recalls and Alerts of InterestDate: 11/26/2008 Reason: Potential risks associated with the use of Bumetanide include serious and significant fluid and electrolyte loss and an elevation in uric acid concentrations. Distribution: Nationwide Date: 11/12/2008 Reason: Johnson & Johnson • Merck Consumer Pharmaceuticals Company (JJMCP) is voluntarily recalling approximately 12,000 units of Infants' MYLICON® GAS RELIEF DYE FREE drops (simethicone-antigas) non-staining sold in 1 oz. plastic bottles that were distributed after October 5, 2008 nationwide. Distribution: Nationwide Date: 12/16/2008 Reason: The FDA is concerned that based upon the original health claims made by the company, patients may forgo approved therapies, and that this could result in more severe illness or death. Distribution: Nationwide Date: 12/11/2008 Reason: Potential adverse events related to an error of this type include electrolyte imbalance, cardiac dysfunction, gastrointestinal disturbances, paresthesia and mental confusion. Distribution: Nationwide Date: 10/27/2008 Reason: Over time, wear and fatigue of the percutaneous lead connecting the HeartMate II LVAS blood pump with the System Controller may result in damage that could interrupt pump function, require reoperation to replace the pump and potentially result in serious injury or death. Distribution: Nationwide Date: 12/11/2008 Reason: The recall is effective immediately and is being undertaken because these lots of STARCAPS contain an undeclared drug ingredient- Bumetanide – a diuretic available by prescription only. Distribution: Nationwide |
|
© 2000 - 2009 Copyright. All rights reserved nola3, llc.






